← Browse by Condition
Medical Condition
graves ophthalmopathy
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3, EARLY_Phase 1
NCT06112340 Phase 2, Phase 3
Recruiting
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Enrollment
75 pts
Location
United States
Sponsor
Sling Therapeutics, Inc.
NCT03708627 EARLY_Phase 1
Recruiting
Bimatoprost as a Treatment for Graves' Orbitopathy
Enrollment
3 pts
Location
United States
Sponsor
Johns Hopkins University
NCT06275373
Recruiting
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Enrollment
100 pts
Location
United States
Sponsor
Walter Reed National Military ...